Vasomotor Symptoms of Menopause – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2022 To 2032

Vasomotor Symptoms of Menopause Market Outlook

Thelansis’s “Vasomotor Symptoms of Menopause Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2022 To 2032" covers disease overview, epidemiology, drug utilization, prescription share analysis, competitive landscape, clinical practice, regulatory landscape, patient share, market uptake, market forecast, and key market insights under the potential Vasomotor Symptoms of Menopause treatment modalities options for eight major markets (USA, Germany, France, Italy, Spain, UK, Japan, and China).

Vasomotor Symptoms of Menopause Overview

Vasomotor symptoms (VMS), which include hot flashes and night sweats, are commonly considered the primary indications of menopause. These symptoms involve intense heat accompanied by sweating and reddening of the skin, primarily felt around the head, neck, chest, and upper back. The majority of women undergoing the menopausal transition experience VMS. The exact mechanisms behind hot flashes are not fully comprehended. However, they likely result from the complex interplay of various physiological systems in the body's central and peripheral regions. Reproductive hormones are likely to play a crucial role in this process. The age of menopausal onset varies significantly, typically falling between 40 to 55 years of age. In the United States, the average age of onset is approximately 51 years, although female smokers experience this transition about two years earlier. Several key factors increase the risk of experiencing VMS, including lower education levels, smoking, obesity, and negative emotional states.

• Vasomotor symptoms are observed in around 80% of women in the US during the menopausal transition, but their frequency varies daily. On average, women report having 4 to 5 hot flashes daily, although some women may experience as many as 20 daily occurrences.

Geography Covered:

North America- the United States and Canada

Europe- EU5 (Germany, France, Italy, Spain, and the United Kingdom)

Other countries- Japan & China

Study Period: 2022-2032

Current Clinical Practice and Treatment Algorithm

This section of the study covers country-specific current clinical practice, the standard of care, and significant limitations around addressing the unmet needs. Retrospective analysis and bench-marking of clinical study outcomes are presented in terms of Pre-treatment & post-treatment clinical and demographic patient characteristics. Essentially, this section will cover the evolution of the current competitive landscape and its impact on the future treatment paradigm.

KOL Insights:

KOLs across 8 MM markets from the center of Excellence/ Public/ Private hospitals participated in the study. Insights around current treatment landscape, epidemiology, clinical characteristics, future treatment paradigm, and Unmet needs

Market Forecast: Patient Based Forecast Model (MS. Excel Based Automated Dashboard)

- Data Inputs with sourcing

- Market Event and Product Event

- Country-specific Forecast Model

- Market uptake and patient share uptake

- Attribute Analysis

- Analog Analysis

- Disease burden and pricing scenario

- Summary and Insights

NPV/ IRR Calculator-

Optimization of cash flow/ revenue flow concerning all fixed and variable investments throughout the product development process. The rate of return on an investment is a critical indicator to ensure the profitability and break-even of the project.

Competitive Landscape:

The competitive landscape includes country-specific approved as well as pipeline therapies. Any asset/product-specific designation or review such as Orphan drug designation, Fast track, Priority Review, Breakthrough Therapy Designation, Rare Pediatric Disease Designation, and Accelerated Approval are tracked and supplemented with analyst commentary.

Clinical Trial Assessment-

Detailed clinical trial data analysis and critical product positioning include trial design, primary outcomes, secondary outcomes, dosing and schedules, inclusion and exclusion criteria, recruitment status and essentially covers the reported adverse events. Majorly the trial analysis helps determine the potential of the critical assets and their probable filing and launch date.

Unmet Medical Needs Overview-

This report presents the most important clinical unmet needs in the treatment, according to Thelansis research and analysis. Other essential unmet needs identified through our study include decreased cost burden on patients, improved administration convenience, and improved patient compliance.

Visit our social media pages: